Atrial fibrillation and hypercoagulability: dependent on clinical factors or/and on genetic alterations?

Eleni Hatzinikolaou-Kotsakou1, Zarifis Kartasis, Dimitrios Tziakas

  • 1Academic Cardiology Department, Demokritious University of Thrace, Greece. kokoy@otenet.gr

Insights

Atrial fibrillation patients exhibit a prothrombotic state, with severity differing across paroxysmal, persistent, and permanent forms. Arrhythmia duration independently predicts these changes, and genetic factors may contribute to hypercoagulability.

Area of Science:

  • Cardiology
  • Hematology
  • Genetics

Background:

  • Atrial fibrillation (AF) is linked to increased thromboembolic events due to a prothrombotic state.
  • Differences in this prothrombotic state among AF subtypes (paroxysmal, persistent, permanent) and the impact of arrhythmia duration remain unclear.
  • The role of genetic alterations in hemostatic risk factors in AF-related hypercoagulability requires further investigation.

Purpose of the Study:

  • To investigate differences in the prothrombotic state across clinical AF subgroups.
  • To determine if arrhythmia duration is an independent predictor of the prothrombotic state in AF patients.
  • To explore the contribution of genetic alterations in hemostatic risk factors to hypercoagulability in AF.

Main Methods:

  • Studied 55 chronic non-valvular AF patients (paroxysmal, persistent, permanent) and 17 controls over 23 months.
  • Quantified prothrombotic state via plasma levels of fibrinogen, soluble P-selectin, and von Willebrand factor.
  • Assessed frequencies of Factor V Leiden and Prothrombin G20210A variants.

Main Results:

  • Permanent AF showed significantly higher levels of von Willebrand factor, fibrinogen, and soluble P-selectin compared to controls and paroxysmal AF.
  • Arrhythmia duration (approx. 3 years) independently predicted abnormal levels of these factors.
  • Frequencies of Factor V Leiden (8.9%) and Prothrombin G20210A (6.4%) were higher in AF patients than controls.

Conclusions:

  • Significant differences in the prothrombotic state exist among AF subtypes, with permanent AF being more pronounced.
  • Arrhythmia duration is an independent predictor of hypercoagulability markers in AF.
  • Genetic alterations in hemostatic risk factors may contribute to hypercoagulability in AF patients.
Abstract

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...